Integer Holdings Co. (NYSE:ITGR – Free Report) – Equities research analysts at Zacks Research increased their FY2024 earnings per share (EPS) estimates for Integer in a research report issued to clients and investors on Thursday, November 14th. Zacks Research analyst D. Dey now forecasts that the medical equipment provider will earn $5.32 per share for the year, up from their prior forecast of $5.28. The consensus estimate for Integer’s current full-year earnings is $5.34 per share. Zacks Research also issued estimates for Integer’s Q4 2024 earnings at $1.45 EPS, Q1 2025 earnings at $1.30 EPS, Q2 2025 earnings at $1.45 EPS, Q4 2025 earnings at $1.69 EPS, FY2025 earnings at $5.99 EPS, Q1 2026 earnings at $1.63 EPS and Q2 2026 earnings at $1.57 EPS.
Integer (NYSE:ITGR – Get Free Report) last issued its earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.36 by $0.07. The business had revenue of $431.42 million during the quarter, compared to the consensus estimate of $440.59 million. Integer had a return on equity of 11.63% and a net margin of 6.70%. The company’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same period last year, the company earned $1.27 EPS.
Check Out Our Latest Research Report on Integer
Integer Price Performance
Shares of ITGR stock opened at $133.18 on Monday. The firm’s 50-day moving average is $129.20 and its two-hundred day moving average is $122.66. Integer has a 12 month low of $84.75 and a 12 month high of $140.91. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.28 and a quick ratio of 2.09. The company has a market capitalization of $4.47 billion, a PE ratio of 41.10, a price-to-earnings-growth ratio of 1.91 and a beta of 1.09.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Contravisory Investment Management Inc. grew its holdings in Integer by 55.9% during the 3rd quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 80 shares in the last quarter. Huntington National Bank increased its holdings in Integer by 8,933.3% in the third quarter. Huntington National Bank now owns 271 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 268 shares during the last quarter. Quest Partners LLC raised its stake in Integer by 3,688.9% in the second quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 332 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Integer by 60.9% during the 2nd quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 142 shares during the last quarter. Finally, Innealta Capital LLC acquired a new position in shares of Integer during the 2nd quarter worth about $110,000. 99.29% of the stock is currently owned by hedge funds and other institutional investors.
About Integer
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.
Recommended Stories
- Five stocks we like better than Integer
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- Why Are These Companies Considered Blue Chips?
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- What is MarketRank™? How to Use it
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.